Sector
PharmaceuticalsOpen
₹25Prev. Close
₹23.7Turnover(Lac.)
₹0.13Day's High
₹25Day's Low
₹22.552 Week's High
₹3952 Week's Low
₹19.99Book Value
₹7.4Face Value
₹10Mkt Cap (₹ Cr.)
10.75P/E
16.69EPS
1.42Divi. Yield
011 Mar 2025
12:00 AM
Board Meeting
Agenda : Audited Result
6 Oct 2023
12:00 AM
EGM
8 Jul 2024
12:00 AM
BookCloser
8 Jul 2024
12:00 AM
AGM
Announcement Date: 08 Jul, 2024
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 4.48 | 4.48 | 4.48 | 4.48 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -1.75 | -2.03 | -2.31 | -2.56 |
Net Worth | 2.73 | 2.45 | 2.17 | 1.92 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 9.95 | 10.6 | 11.29 | 12.24 |
yoy growth (%) | -6.09 | -6.13 | -7.72 | 18.08 |
Raw materials | -7.55 | -8.2 | -9.44 | -10.37 |
As % of sales | 75.88 | 77.36 | 83.64 | 84.72 |
Employee costs | -0.47 | -0.44 | -0.44 | -0.39 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 0.1 | 0.3 | 0.26 | 0.29 |
Depreciation | -0.08 | -0.07 | -0.1 | -0.08 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | 0.12 | 0.86 | 0.28 | 0.14 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -6.09 | -6.13 | -7.72 | 18.08 |
Op profit growth | -44.02 | -27.63 | -9.26 | 3.42 |
EBIT growth | -35.35 | 52.71 | -29.8 | 10.44 |
Net profit growth | -66.42 | 17.43 | -11.15 | 14.86 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,766.2 | 134.52 | 4,23,770.54 | 1,181.05 | 0.76 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,958.35 | 76.3 | 1,58,175.47 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,486.75 | 25.8 | 1,20,075.94 | 1,438.15 | 0.87 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183 | 59.05 | 1,07,722.35 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,434.1 | 51.93 | 1,00,425.74 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Krutiben M Patel
Independent Director
Hasmukh S Darji
Chairman (Non-Executive)
Jashodaben S Patel
Independent Director
Jitendrakumar Parshottamdas Limbachiya
Company Sec. & Compli. Officer
Jigar Ray
Independent Director
Mustufa Najmuddin
Executive Director
Esham. Patel
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Unjha Formulations Ltd
Summary
Unjha Formulations Ltd was established in Jun.87 as a partnership firm for manufacturing pharmaceutical formulations in the Mehsana district of Gujarat. It was promoted by Shambhubhai A Patel. The Company is a pioneer in Isabgol (Psyllium) Formulation. The Company is in service to Isabgol (Psyllium) Ayurvedic formulation profession. The company manufactures pharmaceutical formulations like liquids, powder, tablets, capsules, injectibles, etc. It is one of the largest manufacturers of isabgul products in India. The companys products are classified under two divisions -- human consumption and veterinary products. Its parent company M/S Urvesh Ltd. is 100% EOU is engaged in exporting of Isabol Husk & Isabgol Powder. The Company is a modern manufacturing plant, having GMP Certificate. It is a manufacturer of all kinds of Small Volume Ayurvedic Isabgol (Psyllium) powder and tested at their plant with their modern & well equipped physico chemical and Micro Biological quality control laboratory.Company launched four new products viz.Bericof, Protobal-NT, Formentin Tablets and Nalizole in the year 1997-98. The Company commenced its commercial production and was successfully expanding its customer base throughout the Country including U.P. Territory. Company also interested on development of Export Markets for Ferrous Sulphate, Albendazole Bolus and Iron Folic Tablets to supplement the present law domestic demand situation and achieved export turnover of Rs.0.98 during the year 1997-9
Read More
What is the Unjha Formulations Ltd share price today?
The Unjha Formulations Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹23.99 today.
What is the Market Cap of Unjha Formulations Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Unjha Formulations Ltd is ₹10.75 Cr. as of 09 May ‘25
What is the PE and PB ratio of Unjha Formulations Ltd?
The PE and PB ratios of Unjha Formulations Ltd is 16.69 and 3.20 as of 09 May ‘25
What is the 52 Week High and Low of Unjha Formulations Ltd?
The 52-week high/low is the highest and lowest price at which a Unjha Formulations Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Unjha Formulations Ltd is ₹19.99 and ₹39 as of 09 May ‘25
What is the CAGR of Unjha Formulations Ltd?
Unjha Formulations Ltd's CAGR for 5 Years at 32.88%, 3 Years at 32.02%, 1 Year at 7.34%, 6 Month at -28.83%, 3 Month at -6.95% and 1 Month at 7.00%.
What is the shareholding pattern of Unjha Formulations Ltd?
The shareholding pattern of Unjha Formulations Ltd is as follows:
Promoters - 36.92 %
Institutions - 0.00 %
Public - 63.08 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
